Datapoints: The ups and downs of dosing second-generation antipsychotics

Psychiatric Services

Volumn 58, Issue 1, 2007, Pages 11-

  Citrome, Leslie ^a,b   Jaffe, Ari ^a,b   Levine, Jerome ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; OLANZAPINE; QUETIAPINE; ZIPRASIDONE;

DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG MEGADOSE; HUMAN; MENTAL DISEASE; SHORT SURVEY;

EID: 33847045551     PISSN: 10752730     EISSN: None     Source Type: Journal    
DOI: 10.1176/ps.2007.58.1.11     Document Type: Short Survey

References (3)

1. Citrome L, Jaffe A, Levine J: Dosing of second-generation antipsychotic medication in a state hospital system. Journal of Clinical Psychopharmacology 25:388-391, 2005
2. Hamelin BA, Allard S, Laplante L, et al: The effects of timing of a standard meal on the pharmacokinetics and pharmacodynamics of the novel atypical antipsychotic agent ziprasidone. Pharmacotherapy 18:9-15, 1998
3. Burris KD, Molski TF, Xu C, et al: Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. Journal of Pharmacology and Experimental Therapeutics 302:381-389, 2002